According to a Phase 3b open-label study, Ocrevus may interfere with the effectiveness of non-live vaccines.
Pediatric MS is predominantly inflammatory in nature, with a presentation that is similar to a number of other conditions.
Having a higher burden of comorbidities is associated with greater disability progression and lower QoL, as well as increased healthcare utilization and mortality.
Investigators sought to determine relapse rates of multiple sclerosis decrease prior to pregnancy, during pregnancy, and postpartum.
Investigators propose that myelocortical multiple sclerosis may be a subtype of multiple sclerosis.
Cannabinoids may be mildly effective at treating spasticity, pain, and bladder dysfunction in adults with multiple sclerosis.
Fingolimod shows superior efficacy to interferon beta-1a in pediatric multiple sclerosis: the PARADIGMS trialOctober 17, 2018
Among pediatric patients with relapsing multiple sclerosis, fingolimod was associated with a lower annualized rate of relapse and lower incidence of new lesions identified on T2-weighted magnetic resonance imaging (MRI) compared to interferon beta-1a.
Investigators examine the role of physical activity and exercise in the modification of vascular comorbidities and risk factors in individuals with multiple sclerosis.
All participants were smokers or had either diabetes, cancer, depression, cardiovascular, respiratory, thyroid, or gastrointestinal disease and were receiving a DMT.
Natural history data from a subset of patients from the British Columbia MS database between 1980 to 1996 were used to create a continuous Markov model to model the projected course of disease in untreated people with RMS.
Compared with Copaxone injection, treatment with oral Gilenya significantly reduced the annualized relapse rate in patients with relapsing remitting multiple sclerosis.
Researchers categorized samples into quintiles based on 25(OH)D3 concentrations in healthy controls.
Patients with progressive MS or secondary progressive MS who were receiving care at a single institution in France were prescribed 300 mg/day MD1003.
Disability progression is slower among patients with pediatric-onset multiple sclerosis.
In patients with relapse-remitting multiple sclerosis, the initiation of oral disease-modifying therapies is associated with a lower relapse risk as well as a lower risk for disability progression.
Investigators examine the effect of disease-modifying therapy on the rate of brain atrophy in patients with multiple sclerosis.
Patients with MS also have a higher risk for serious hospitalized-related infections compared with hospitalized patients without MS.
Study investigators assessed the changes in the Expanded Disability Status Scale and MS Severity Score after up to 7 courses of alemtuzumab.
The phase 3 PARADIGMS trial involving 215 pediatric patients demonstrated superior efficacy for fingolimod over interferon beta-1a.
Patients were divided into 3 groups: patients not treated in the 3 months before pregnancy, patients treated in the 3 months before pregnancy, and patients treated during pregnancy.
Treatments were evaluated for either 1 year (SUNBEAM) or 2 years (RADIANCE).
Participants showed a significant decrease in annual relapse rate and a significant improvement in both patient-reported disability scores and information processing scores.
Researchers pooled long-term data on the safety of cladribine tablets monotherapy that extended 3 or more years beyond the data included in the last clinical study.
Investigators examined factors associated with mobility and walking restrictions in participants with multiple sclerosis.
Surveys were given out to individuals in the Australian Multiple Sclerosis Longitudinal Study between August and December 2016.
Researchers analyze the dietary habits of 260 patients in the early stages of multiple sclerosis from baseline to 5 years after initial onset of symptoms.
Evidence suggests a possible role for inflammation in the association between MS and myocardial infarction risk.
Reserachers evaluated data from the CLARITY study to test the efficacy of cladribine tablets on frequency and severity of relapses for patients with multiple sclerosis.
Patients with multiple sclerosis who initiated ocrelizumab therapy earlier and continued long-term treatment sustained lower annualized relapse rates.
The ESTEEM study included 3075 patients who were newly prescribed dimethyl fumarate to manage relapsing-remitting multiple sclerosis.
Neurology Advisor Articles
- Multiple System Atrophy: A Common Form of Atypical Parkinsonism
- Migraine Treatment in the ED: Overcoming Our Penchant for Opioids
- Erenumab as a Therapy for Hard to Treat Episodic Migraine
- Nusinersen May Be Effective for Short-Term Motor Function Improvements in Spinal Muscular Atrophy
- Reduced Survival for Patients With Idiopathic Parkinsonism
- New Diagnostic Criteria for Neurosarcoidosis: What You Need to Know
- Guideline for Diagnosis and Treatment of Idiopathic Intracranial Hypertension
- Guidelines on the Use of OnabotulinumtoxinA for Chronic Migraine
- Ivy League Rule Change Linked to Fewer Concussions During NCAA Football Games
- Biomarkers of Alzheimer Disease Observed in Down Syndrome
- Ocrevus Labeling Updated With New Info on Timing of Vaccine Administration
- Approaches for Better Diagnosis of Pediatric Multiple Sclerosis
- Short Segment Sensory Nerve Stimulation Offers Potential Diagnostic Value for Ulnar Neuropathy
- Incidence of Guillain-Barré Syndrome Linked With Recent Bone, Digestive Organ Surgery
- Online Tool Helps Patients With Advance Care Planning